Robert A. Forbes, PhD

Higher patient cost-sharing is associated with a lower likelihood of treatment augmentation in patients with depression who are treated with antidepressants.

In treatment of depression with adjunctive aripiprazole, early improvement (week 2) was a significant predictor of remission, and lack of improvement was associated with nonremission.